H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Acurx Pharmaceuticals to $12 from $14 and keeps a Buy rating on the shares following the Q4 report. The company announced plans to initiate the first of two registrational Phase 3 trials of ibezapolstat as a treatment for patients with clostridioides difficile infection in Q4, with a goal to complete in a year and a half, or in Q2 of 2026, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACXP:
- Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
- Acurx’s ibezapolstat granted end of Phase 2 meeting by FDA, EMA SME designation
- Acurx’s antibiotic candidate shows positive Phase 2b clinical cure data
Questions or Comments about the article? Write to editor@tipranks.com